EGFR Testing Kit - Cancer Diagnostics Plasma & Tissue-Based Mutation Detection
EGFR Kit Plasma
The kit is used in the examination of patients diagnosed with non-small cell lung cancer (NSCLC) to determine indications for targeted therapy with the EGFR tyrosine kinase inhibitors and monitor the response to them. The liquid biopsy method allows for continuous monitoring of the patient's condition and making prompt changes to the treatment program.
• Detection of 29 mutations in the EGFR gene & can be used when adequate tumor material is not available.
EGFR Kit Tissue-Multi
The kit is used in the examination of patients diagnosed with non-small cell lung cancer stage IB–IIIA and IV of the disease to determine indications for targeted therapy with the EGFR tyrosine kinase inhibitors and monitor response to them.
• Detection of 48 mutations in the EGFR gene.
• The risk of contamination is reduced due to the inclusion of uracil-DNA-glycosylase (UDG) and 2'-deoxyuridine-5'-triphosphate (dUTP) in the reaction mix.
✅The kit is compatible with almost all RT-PCR devices.
Features & Characteristics
| Detection Method | Real-Time PCR (melting curves) |
|---|---|
| Format | Qualitative Multiplex (Tissue), Qualitative Monoplex (Plasma) |
| Sample |
Blood Plasma (Plasma) Formalin-fixed, Paraffin-embedded tissue (FFPE-blocks) (Tissue) |
| Detection of Mutations |
Plasma : L858R, T790M, 27 deletions (del) in exon 19 Tissue-Multi: Exon 18 detects the G719S, G719C, G719D, G719A mutations Exon 19 detects 35 mutations Exon 20 detects the S768I, T790M mutations Exon 21 detects the L858R and L861Q mutations |
| Number of Reactions | 24 Reactions |
| Test Time | 120 Minutes (Plasma)/ 60 Minutes (Tissue-Multi) |
| Recommended Extraction Kit | DNA Tissue-100 (Tissue-Multi)/ DNA-PM-RT-50 |
Test Method
